#United States #New York #Gross Law Firm #Immutep Limited #TACTI-004 Trial

Immutep Limited Faces Securities Class Action Lawsuit

Overview

In recent developments, The Gross Law Firm has issued an alert addressing shareholders of Immutep Limited (NASDAQ: IMMP). This announcement arises amidst significant losses reported by investors who acquired shares during a specific class period from March 24, 2025, to March 12, 2026. The law firm is encouraging affected shareholders to reach out regarding their potential involvement in a class action lawsuit geared towards recovering losses sustained during this period.

Class Period and Allegations

The class period in question is crucial for those interested in participating in the lawsuit. Purchasers of IMMP shares during this timeframe are urged to act now to ensure their potential recovery. According to the complaint, serious allegations have been made against the company, suggesting it provided misleading information regarding the efficacy and safety associated with its TACTI-004 Phase III clinical trial. The breach of trust appears to be manifest in the disparity between optimistic statements by the defendants and the underlying adverse facts which were concealed.

Events Leading to the Lawsuit

On March 13, 2026, a critical press release from Immutep revealed that the Independent Data Monitoring Committee (IDMC) had advised that the TACTI-004 Phase III trial be halted. This was based on an interim futility analysis which assessed the safety and efficacy data available at that time. The stark conclusion led to the decision to terminate the trial, marking a pivotal moment for the company and its investors. The aftermath saw a dramatic plunge in Immutep's stock price, plummeting about 83% from $2.76 per share on March 12 to a mere $0.48 the following day.

Next Steps for Shareholders

Shareholders who believe they have experienced losses and wish to participate in this class action are encouraged to register their information through the provided links. The Gross Law Firm has streamlined the process to ensure ease of access for investors, enabling them to enroll in a portfolio monitoring service. This service will provide them with updates and insights throughout the duration of the lawsuit. Notably, there are no costs associated with joining this class action, and there is no obligation to act as a lead plaintiff, although those interested in this role can register before the July 6, 2026 deadline.

The Role of The Gross Law Firm

The Gross Law Firm stands as a nationally recognized class action law firm dedicated to defending the rights of investors who have been subjected to fraudulent practices and deceitful business dealings. Its mission focuses on ensuring corporations are held accountable for their actions, and that rightful recovery paths are made available to those who have suffered losses due to misleading statements or omissions by a company.

Conclusion

For shareholders of Immutep Limited, this class action lawsuit represents an important opportunity for potential recovery of significant financial losses. Given the outlined circumstances and the expedited timelines, all affected shareholders are strongly encouraged to reach out to The Gross Law Firm to ascertain their eligibility and potential next steps. This proactive measure could be vital in addressing the repercussions suffered from the abruptly halted clinical trial efforts and the associated loss in stock value.

For more detailed information on how to claim your eligibility and register your information, please visit the provided links or contact The Gross Law Firm directly.

Contact Information

• - The Gross Law Firm

15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

This notice stands critical for Immutep investors, marking a pivotal moment to reclaim losses that may have occurred due to corporate misleadership.